Cytokine profile in synovial fluid from patients with internal derangement of the temporomandibular joint: A preliminary study

Dentomaxillofacial Radiology

Volumn 35, Issue 6, 2006, Pages 432-441

  Matsumoto, K ^a   Honda, K ^a   Ohshima, Mitsuhiro ^a   Yamaguchi, Y ^a   Nakajima, I ^a   Micke, P ^b   Otsuka, K ^a  

^a NIHON UNIVERSITY   (Japan)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Cytokine; Joint effusion; Synovial fluid; Temporomandibular joint

Indexed keywords

ANGIOGENIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 9; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 8; LYMPHOTOXIN; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; OSTEOPROTEGERIN; PULMONARY AND ACTIVATION REGULATED PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA2; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; JOINT EFFUSION; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDER;

ADULT; AGED; CHEMOKINES, CXC; CYTOKINES; FEMALE; FIBROBLAST GROWTH FACTOR 9; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INTERFERON TYPE II; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-8; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MIDDLE AGED; OSTEOPROTEGERIN; RIBONUCLEASE, PANCREATIC; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TRANSFORMING GROWTH FACTOR BETA2; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33845383621     PISSN: 0250832X     EISSN: None     Source Type: Journal    
DOI: 10.1259/dmfr/77288976     Document Type: Article

References (48)

1. Ireland VE. Problem of "the clicking jaw". Dent Dig 1951; 57: 549-554.
2. Dimitroulis G. The role of surgery in the management of disorders of the temporomandibular joint: a critical review of the literature. Part 1. Int J Oral Maxillofac Surg 2005; 34: 107-113.
3. Green CS, Olson RE. Laskin DM. Psychological factors in the etiology, progression, and treatment of MPD syndrome. J Am Dent Assoc 1982; 105: 443-448.
4. Kaplan PA, Tu HK, Sleder PR, Lydiatt DD, Laney TJ. Inferior joint space arthrography of normal temporomandibular joints: reassessment of diagnostic criteria. Radiology 1986; 159: 585-589.
5. De Bont LG, Boering G, Liem RS, Eulderink F, Westesson PL. Osteoarthritis and internal derangement of the temporomandibular joint: a light microscopic study. J Oral Maxillofac Surg 1986; 44: 634-643.
6. De Bont LG, Stegenga B. Pathology of temporomandibular joint internal derangement and osteoarthrosis. Int J Oral Maxillofac Surg 1993; 22: 71-74.
7. Kacena MA, Merrel GA, Konda SR, Wilson KM, Xi Y, Horowitz MC. Inflammation and bony changes at the temporomandibular joint. Cells Tissues Organs 2001; 169: 257-264.
8. Fu K, Ma X, Zhang Z, Chen W. Tumor necrosis factor in synovial fluid of patients with temporomandibular disorders. J Oral Maxillofac Surg 1995; 53: 424-426.
9. Takahashi T, Kondoh T, Fukuda M, Yamazaki Y, Toyosaki T, Suzuki R. Proinflammatory cytokines detectable in synovial fluids from patients with temporomandibular disorders. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 85: 135-141.
10. Kubota E, Kubota T, Matsumoto J, Shibata T, Murakami KI. Synovial fluid cytokines and proteinases as markers of temporomandibular joint disease. J Oral Maxillofac Surg 1998; 56: 192-198.
11. Kaneyama K, Segami N, Sato J, Nishimura M, Yoshimura H. Interleukin-6 family of cytokines as biochemical markers of osseous changes in the temporomandibular joint disorders. Br J Oral Maxillofac Surg 2004; 42: 246-250.
12. Shinoda C, Takaku S. Interleukin-1 beta, interleukin-6, and tissue inhibitor of metalloproteinase-1 in the synovial fluid of the temporomandibular joint with respect to cartilage destruction. Oral Dis 2000; 6: 383-390.
13. Segami N, Miyamaru M, Nishimura M, Suzuki T, Kaneyama K, Murakami K. Does joint effusion on T2 magnetic resonance images reflect synovitis? Part 2. Comparison of concentration levels of proinflammatory cytokines and total protein in synovial fluid of the temporomandibular joint with internal derangement and osteoarthrosis. Oral Surg Oral Med Oral Pathol Oral Radiol Ended 2002; 94: 512-521.
14. Kaneyama K, Segami N, Nishimura M, Suzuki T, Sato J. Importance of proinflammatory cytokine in synovial fluid from 121 joints with temporomandibular disorders. Br J Oral Maxillofac Surg 2002; 40: 418-423.
15. Fang PK, Ma XC, Ma DL, Fu KY. Determination of interleukin-1 receptor antagonist, interleukin-10, and transforming growth factor-beta1 in synovial fluid aspirates of patients with temporomandibular disorders. J Oral Maxillofac Surg 1999; 57: 922-928.
16. Nishimura M, Segami N, Kaneyama K, Suzuki T, Miyamaru M. Proinflammatory cytokines and arthroscopic findings of patients with internal derangement and osteoarthritis of the temporomandibular joint. Br J Oral Maxillofac Surg 2002; 40: 68-71.
17. Kaneyama K, Segami N, Nishimura M, Sato J, Suzuki T, Fujimura K. Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. Int J Oral Maxillofac Surg 2003; 32: 404-407.
18. Sato J, Segami N, Kaneyama K, Mashiyama Y, Fujimura K, Yoshitake Y. Vascular endothelial growth factor concentrations in synovial fluids of patients with symptomatic internal derangement of the temporomandibular joint. J Oral Pathol Med 2005; 34: 170-177.
19. Sato J, Segami N, Kaneyama K, Konishi H, Yoshitake Y, Nishikawa K. Levels of fibroblast growth factor 2 in synovial fluids in human patients with internal derangement of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 96: 673-679.
20. Huang RP. Cytokine antibody arrays: a promising tool to identify molecular targets for drug discovery. Comb Chem High Throughput Screen 2003; 6: 769-775.
21. Segami N, Nishimura M, Kaneyama K, Miyamaru M, Sato J, Murakami K. Does joint effusion on T2 magnetic resonance images reflect synovitis? Comparison of arthroscopic findings in internal derangements of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001; 92: 341-355.
22. Westesson PL, Brooks SL. Temporomandibular joint: relationship between MR evidence of effusion and the presence of pain and disk displacement. AJR Am J Roentgenol 1992; 159: 559-563.
23. Honda K, Yonezu H, Takano Y, Kashima M, Sawada K, Arai Y, et al. Image-assisted puncture technique for the superior temporomandibular joint cavity using limited cone beam X-ray CT for dental use (3DX™). Dental Radiology 2003; 43: 17-22. In Japanese.
24. Micke P, Östman A. Tumor-stroma interaction: cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004; 45(Suppl. 2): 163-175.
25. Vila E, Salaices M. Cytokines and vascular reactivity in resistance arteries. Am J Physiol Heart Circ Physiol 2005; 288: 1016-1021.
26. Grignani G, Maiolo A. Cytokines and hemostasis. Haematologica 2000; 85: 967-972.
27. Quinn JH, Bazan NG. Identification of prostaglandin E2 and leukotriene B4 in the synovial fluid of painful, dysfunctional temporomandibular joints. J Oral Maxillofac Surg 1990; 48: 968-971.
28. Holmlund A, Ekblom A, Hansson P, Lind J, Lundeberg T, Theodorsson E. Concentrations of neuropeptides substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid of the human temporomandibular joint. A correlation with symptoms, signs and arthroscopic findings. Int J Oral Maxillofac Surg 1991; 20: 228-231.
29. Kopp S. Neuroendocrine, immune, and local responses related to temporomandibular disorders. J Orofac Pain 2001; 15: 9-28.
30. Sandler NA, Buckley MJ, Cillo JE, Braun TW. Correlation of inflammatory cytokines with arthroscopic findings in patients with temporomandibular joint internal derangements. J Oral Maxillofac Surg 1998; 56: 534-543.
31. Emshoff R, Puffer P, Rudisch A, Gassner R. Temporomandibular joint pain: relationship to internal derangement type, osteoarthrosis, and synovial fluid mediator level of tumor necrosis factor-alpha. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000; 90: 442-449.
32. Badet J. Angiogenin, a potent mediator of angiogenesis. Biological, biochemical and structural properties. Pathol Biol (Paris) 1999; 47: 345-351.
33. Yoshida T, Ishimaru K, Sakamoto H, Yokota J, Hirohashi S, Igarashi K, et al. Angiogenic activity of the recombinant hst-1 protein. Cancer Lett 1994; 83: 261-268.
34. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 1996; 380: 435-439.
35. Brown RA, Weiss JB. Neovascularisation and its role in the osteoarthritic process. Ann Rheum Dis 1988; 47: 881-885.
36. Walsh DA, Pearson CI. Angiogenesis in the pathogenesis of inflammatory joint and lung diseases. Arthritis Res 2001; 3: 147-153.
37. Yoshino H, Morita I, Murota SI, Ishikawa I. Mechanical stress induces production of angiogenic regulators in cultured human gingival and periodontal ligament fibroblasts. J Periodontal Res 2003; 38: 405-410.
38. McQuillan DJ, Handley CJ, Campbell MA, Bolis S, Milway VE, Herington AC. Stimulation of proteoglycan biosynthesis by serum and insulin-like growth factor-I in cultured bovine articular cartilage. Biochem J 1986; 240: 423-430.
39. Oh CD, Chun JS. Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1. J Biol Chem 2003; 278: 36563-36571.
40. Loeser RF, Shanker G, Carlson CS, Gardin JF, Shelton BJ, Sonntag WE. Reduction in the chondrocyte response to insulin-like growth factor 1 in aging and osteoarthritis: studies in a non-human primate model of naturally occurring disease. Arthritis Rheum 2000; 43: 2110-2120.
41. Neidel J, Blum WF, Schaeffer HJ, Schulze M, Schonau E, Lindschau J, et al. Elevated levels of insulin-like growth factor (IGF) binding protein-3 in rheumatoid arthritis synovial fluid inhibit stimulation by IGF-I of articular chondrocyte proteoglycan synthesis. Rheumatol Int 1997; 17: 29-37.
42. Dore S, Pelletier JP, DiBattista JA, Tardif G, Brazeau P, Martel-Pelletier J. Human osteoarthritic chondrocytes possess an increased number of insulin-like growth factor 1 binding sites but are unresponsive to its stimulation. Possible role of IGF-1-binding proteins. Arthritis Rheum 1994; 37: 253-263.
43. De Ceuninck F, Caliez A, Dassencourt L, Anract P, Renard P. Pharmacological disruption of insulin-like growth factor 1 binding to IGF-binding proteins restores anabolic responses in human osteoarthritic chondrocytes. Arthritis Res 2004; 6: 393-403.
44. Roberts L, McColl GJ. Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritis. Intern Med J 2004; 34: 687-693.
45. van den Berg WB. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res 2001; 3: 18-26.
46. Dougados M. Proposed guidelines for the clinical evaluation of interleukin-1 inhibitors in the treatment of rheumatoid arthritis. Eur Cytokine Netw 1990; 1: 235-237.
47. Heldin CH. Development and possible clinical use of antagonists for PDGF and TGF-beta. Ups J Med Sci 2004; 109: 165-178.
48. Brenchley PE. Angiogenesis in inflammatory joint disease: a target for therapeutic intervention. Clin Exp Immunol 2000; 121: 426-429.